Sanofi (NASDAQ:SNY) is a global biopharmaceutical company headquartered in Paris, France, specializing in the research, development, manufacturing and marketing of prescription medicines, vaccines and consumer healthcare products. With a focus on addressing high unmet medical needs, Sanofi’s operations span a broad range of therapeutic areas, including immunology, oncology, cardiovascular disease, diabetes, central nervous system disorders and rare diseases.
The company’s vaccine business, operated under Sanofi Pasteur, is one of the world’s largest vaccine producers, supplying immunizations against influenza, meningitis, yellow fever, polio and other infectious diseases. Sanofi also supports patients through its specialty care division, which originated with the acquisition of Genzyme in 2011 and is dedicated to rare genetic disorders and multiple sclerosis therapies. In addition, the firm markets several prescription medicines for chronic conditions such as type 2 diabetes and cardiovascular risk management.
Sanofi maintains a presence in more than 100 countries, with major research and production facilities in Europe, North America and emerging markets across Asia, Latin America and Africa. The company collaborates with academic institutions, biotech firms and public health organizations to advance its pipeline of vaccines, biologics and small-molecule therapies. Through these partnerships, Sanofi aims to accelerate the development of innovative treatments and improve access to medicines worldwide.
Founded through a series of mergers—most notably the creation of Sanofi-Synthélabo in 1999 and the subsequent integration of Aventis in 2004—Sanofi traces its roots back to mid-1970s pharmaceutical ventures in France. Since September 2019, Paul Hudson has served as Chief Executive Officer, directing the company’s strategic priorities toward research investment, operational efficiency and sustainable growth in global healthcare markets.
